InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: BTH post# 991

Thursday, 07/22/2010 10:46:35 AM

Thursday, July 22, 2010 10:46:35 AM

Post# of 80490
With both gleevec and tasigna, novartis is probably out. BMS could be interesting but risky in that 534 may end up with short shrift vis a vi sprycel. I'm also not in love with the idea of MRK in control of both rida and 534...basically that's akin to selling the company but without the benefit of shareholders getting paid.

Of course ariad could just partner non-US and keep 100% US but that would be a mistake, imo, in terms of maximizing the value of 534 (but it would facilitate Bergers goal of building a stand-alone oncology company)

To maximize 534's value you need multiple bidders but unfortunately none of the best players are a great fit. What do you think about Pfizer as a possibility?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.